Page 305 - An Evidence Review of Active Surveillance in Men With Localized Prostate Cancer

Appendix Table C1.9. Tumor characteristics—PSA (continued)
Author Database PSA groups 1980- 1985-89 1990-94 1995-99 2000-04 2005-10 Statistical Notes
Year (ng/ml) 84 analysis
PMID
68
Cooperberg CaPSURE <2 9.2% 4.8% 6.4% 5.8% P<0.001 Information on
2007 2-6 42.9% 48.3% 62.0% 65.9% (“trend in trends was reported
17644125 6-10 47.8% 46.9% 31.6% 28.2% distribution of only for patients
(1990- (1995- (2002-03) (2004- each risk with “low-risk”
94) 99) 06) characteristic”) prostate cancer,
defined as PSA≤10
ng/ml, Gleason
score≤6 and clinical
stage T1/T2a.
Cooperberg 111 CaPSURE 0-10 34.3% 51.8% 58.5% 60.6% High risk localized
2008 10.01-20 23.3% 18.3% 14.8% 14.9% P<0.001 prostate cancer
18369637 20.01-30 16.8% 13.2% 10.9% 10.7% (Cuzick test for only
>30 25.6% 16.7% 15.8% 13.8% trend)
(1990- (1995- (2002-03) (2004-
94) 99) 07)
71
Greene CaPSURE ≤4 15% 16% P=0.008
2005 4.1-10 60% 67% (chi-square
16194711 10.1-20 18% 13% comparing 2
>20 7% 4% periods)
(1997- (2000-03)
99)
77
Hamilton POCS, 0-4.0 9.1% 14.4% P<0.01
2011 NCI 4.1-9.9 53.5% 51.1% (difference in
20735387 10.0-19.9 19.3% 12.0% distribution by yr)
20.0-100.0 6.2% 6.2%
>100.0 0.1% 1.1%
unknown 11.8% 15.2%
(1998) (2002)
Ordering of the studies follows Appendix Table C1.1.
NA = not applicable; NR = not reported; PMID = PubMed identification number; PSA = prostate specific antigen.

C-70